Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma

BACKGROUND: Targeting human epidermal growth factor receptor 2 (HER2) with trastuzumab in metastatic esophagogastric adenocarcinoma (EGA) improves survival. The impact of HER2 inhibition in combination with chemoradiotherapy (CRT) in early stage EGA is under investigation. This study analyzed the pa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Gastrointest Oncol
Main Authors: Chan, Ellie, Duckworth, Lizette Vila, Alkhasawneh, Ahmad, Toro, Tania Zuluaga, Lu, Xiaomin, Ben-David, Kfir, Hughes, Steven J., Rossidis, Georgios, Zlotecki, Robert, Lightsey, Judith, Daily, Karen C., Dang, Long, Allegra, Carmen J., King, Brent, George, Thomas J.
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2016
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4783750/
https://ncbi.nlm.nih.gov/pubmed/27034783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2078-6891.2015.071
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados